Advertisement
CGC vs TLRY
Which Stock Would AI Choose? Canopy Growth (CGC) vs. Tilray Brands (TLRY) Stock Comparison
Key Takeaways
- Canopy Growth (CGC) is a pure-play Canadian cannabis operator executing a multi-year turnaround, while Tilray Brands (TLRY) is a diversified cannabis and consumer packaged goods (CPG) company with a large craft-beverage business.
- CGC trades in penny-stock territory below $1 and has faced substantial share dilution, whereas TLRY operates at a materially larger revenue base of roughly $1.2 billion on an annualized basis.
- Recent quarters show narrowing losses at Canopy Growth, while Tilray has posted record revenue and guided toward positive, growing adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).
- Tickeron AI Verdict: TLRY — Tilray Brands is favored on the strength of its more stable, diversified revenue mix and clearer path to profitability.
- Both names remain highly sensitive to U.S. cannabis rescheduling and legalization headlines, which can drive sharp, sentiment-led swings.
- For deeper coverage, explore CGC Major News and CGC Today's Price Move, as well as TLRY Major News and TLRY Today's Price Move.
- To see how automated strategies are positioning across the market, explore the Trending AI Robots page.
Introduction
Canopy Growth and Tilray Brands are two of the most widely followed names in the North American cannabis sector, yet they represent sharply different business models. This stock comparison is relevant for traders and investors weighing a pure-play cannabis turnaround story against a diversified cannabis-and-beverage operator. Both companies have been reshaped by strategic moves in recent quarters — acquisitions, recapitalizations, and restructuring — and both remain exposed to shifting U.S. regulatory sentiment. Understanding their relative performance and market positioning can help readers assess which structure is better suited to the current environment.
CGC Overview and Recent Performance
Canopy Growth Corporation is a Canadian cannabis company with a portfolio spanning medical and adult-use cannabis, international markets, and the Storz & Bickel vaporizer brand. In recent weeks the company has emphasized a turnaround under a cost-discipline strategy, including a strategic recapitalization that extended debt maturities to 2031 and shifted its balance sheet to a net cash position. The acquisition of MTL Cannabis has positioned Canopy as Canada's leading medical cannabis provider by revenue.
Recent market activity shows improving fundamentals offset by persistent concerns. Net revenue has grown at a double-digit pace, gross margin has expanded, and net losses have narrowed meaningfully. However, the stock remains below $1 per share, reflecting two overhangs: heavy share-count growth from equity raises and uncertainty over U.S. federal legalization progress. Sentiment remains cautious, with investors weighing operational gains against dilution risk.
TLRY Overview and Recent Performance
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company operating across cannabis, beverage, wellness, and distribution, with more than 40 brands in over 20 countries. Its beverage segment — including craft beer brands and a growing partnership with Carlsberg — is a major differentiator. Recent quarters have delivered record net revenue, with beverage sales growing sharply and international cannabis revenue expanding across Germany, the U.K., and Poland.
The company has guided toward increasing adjusted EBITDA while reducing debt and restructuring both its Canadian cannabis operations and U.S. beverage footprint to capture annualized cost savings. Still, cannabis revenue has declined year over year, and the company continues to report a net loss. Elevated short interest and a micro-cap valuation contribute to volatility. In recent weeks, Tilray raised the lower end of its adjusted EBITDA outlook, supporting a modestly firmer tone in sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection from among hundreds of available AI trading bots that collectively trade thousands of different tickers. Rather than listing every strategy, this section highlights only the bots best suited to current market conditions. Each bot differs in trading style, strategy, timeframe, performance statistics, and the set of tickers it trades, so the page serves as a shortlist of strategies that have recently demonstrated alignment with prevailing trends. For traders evaluating names like CGC and TLRY, this can offer a data-driven lens on momentum and positioning. Explore Trending AI Robots to review the current selection.
Head-to-Head Comparison
The two companies diverge most clearly in business model and scale. Canopy Growth is concentrated in cannabis, with higher sensitivity to sector-specific catalysts such as Canadian pricing and U.S. rescheduling. Tilray Brands is diversified, using a large beverage and distribution business to offset cannabis volatility. Growth drivers also differ: Canopy leans on medical cannabis and international expansion, while Tilray emphasizes beverage scale, international cannabis, and cost restructuring.
On recent momentum, Tilray's record revenue and EBITDA guidance contrast with Canopy's narrower-loss narrative and sub-$1 share price. Risk factors likewise differ — Canopy's primary concern is dilution, while Tilray's is elevated short interest and integration of acquisitions such as BrewDog. In market positioning, Tilray's broader revenue base and progress toward positive adjusted EBITDA currently present a more balanced risk profile than Canopy's earlier-stage turnaround.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would currently favor TLRY. Tilray Brands exhibits a more diversified and stable revenue base, record top-line performance, and a clearer near-term path to positive and growing adjusted EBITDA, alongside a strengthened balance sheet. By comparison, Canopy Growth's turnaround is encouraging but remains weighed down by heavy dilution, a sub-$1 share price, and continued net losses. While both stocks carry meaningful risk and remain sensitive to regulatory headlines, Tilray's relative positioning is currently more consistent across trend, stability, and catalyst quality.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGC is a Hold and TLRY is a StrongBuy.
CGC in +10.41% Uptrend, rising for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CGC advanced for three days, in 162 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CGC's RSI Oscillator exited the oversold zone, 35 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 75 cases where CGC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CGC just turned positive on November 02, 2026. Looking at past instances where CGC's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGC as a result. In 78 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CGC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CGC entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (7.254). P/E Ratio (-0.972) is within average values for comparable stocks, (0.575). CGC's Projected Growth (PEG Ratio) (7.200) is slightly higher than the industry average of (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (1.549) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Momentum Indicator for TLRY turns positive, indicating new upward trend
TLRY saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In 63 of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Oscillator exited the oversold zone, 39 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for TLRY just turned positive on November 04, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.
Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLRY entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (7.254). P/E Ratio (-2.679) is within average values for comparable stocks, (0.575). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
CGC | TLRY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 93 | |
PRICE GROWTH RATING 1..100 | 81 | 86 | |
P/E GROWTH RATING 1..100 | 15 | 15 | |
SEASONALITY SCORE 1..100 | n/a | 3 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TLRY's Valuation (22) in the Biotechnology industry is somewhat better than the same rating for CGC (83) in the Agricultural Commodities Or Milling industry. This means that TLRY’s stock grew somewhat faster than CGC’s over the last 12 months.
TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CGC (100) in the Agricultural Commodities Or Milling industry. This means that TLRY’s stock grew similarly to CGC’s over the last 12 months.
TLRY's SMR Rating (93) in the Biotechnology industry is in the same range as CGC (97) in the Agricultural Commodities Or Milling industry. This means that TLRY’s stock grew similarly to CGC’s over the last 12 months.
CGC's Price Growth Rating (81) in the Agricultural Commodities Or Milling industry is in the same range as TLRY (86) in the Biotechnology industry. This means that CGC’s stock grew similarly to TLRY’s over the last 12 months.
CGC's P/E Growth Rating (15) in the Agricultural Commodities Or Milling industry is in the same range as TLRY (15) in the Biotechnology industry. This means that CGC’s stock grew similarly to TLRY’s over the last 12 months.
| CGC | TLRY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 80% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| Advances ODDS (%) | 3 days ago 81% | 3 days ago 79% |
| Declines ODDS (%) | 1 day ago 90% | 8 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 89% | N/A |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGC’s FA Score shows that 1 FA rating(s) are green while TLRY’s FA Score has 2 green FA rating(s).
- CGC’s FA Score: 1 green, 4 red.
- TLRY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGC’s TA Score shows that 4 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).
- CGC’s TA Score: 4 bullish, 4 bearish.
- TLRY’s TA Score: 4 bullish, 3 bearish.
Price Growth
CGC (@Pharmaceuticals: Generic) experienced а -0.15% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was +15.42% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.04%. For the same industry, the average monthly price growth was -9.05%, and the average quarterly price growth was +4.62%.
Reported Earning Dates
CGC is expected to report earnings on Feb 05, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-1.04% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
TLRY and
Correlation & Price change
A.I.dvisor indicates that over the last year, TLRY has been closely correlated with SNDL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To TLRY | 1D Price Change % | ||
|---|---|---|---|---|
| TLRY | 100% | +3.91% | ||
| SNDL - TLRY | 76% Closely correlated | +2.54% | ||
| CGC - TLRY | 75% Closely correlated | -3.58% | ||
| ACB - TLRY | 65% Loosely correlated | +0.96% | ||
| CRON - TLRY | 64% Loosely correlated | -2.96% | ||
| GLAS - TLRY | 59% Loosely correlated | -6.73% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| PEOPLE.X | 0.006149 | 0.000243 | +4.12% |
| ConstitutionDAO cryptocurrency | |||
| MAV.X | 0.007824 | 0.000296 | +3.93% |
| Maverick Protocol cryptocurrency | |||
| ZEC.X | 1320.165800 | 47.215088 | +3.71% |
| Zcash cryptocurrency | |||
| AXS.X | 0.843138 | 0.022945 | +2.80% |
| Axie Infinity cryptocurrency | |||
| MITH.X | 0.000337 | N/A | N/A |
| Mithril cryptocurrency | |||